Free Trial

COMPASS Pathways (CMPS) Competitors

COMPASS Pathways logo
$4.70 +0.09 (+1.97%)
As of 01:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CMPS vs. IMCR, AUPH, CDTX, WVE, JANX, SDGR, EWTX, HROW, ARDX, and ETNB

Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), WAVE Life Sciences (WVE), Janux Therapeutics (JANX), Schrodinger (SDGR), Edgewise Therapeutics (EWTX), Harrow (HROW), Ardelyx (ARDX), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry.

COMPASS Pathways vs. Its Competitors

COMPASS Pathways (NASDAQ:CMPS) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Immunocore has higher revenue and earnings than COMPASS Pathways. Immunocore is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
COMPASS PathwaysN/AN/A-$155.12M-$1.84-2.56
Immunocore$310.20M5.30-$51.09M-$0.40-81.49

COMPASS Pathways has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

COMPASS Pathways currently has a consensus price target of $16.29, suggesting a potential upside of 245.18%. Immunocore has a consensus price target of $56.89, suggesting a potential upside of 74.52%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, research analysts plainly believe COMPASS Pathways is more favorable than Immunocore.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
COMPASS Pathways
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Immunocore
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.55

COMPASS Pathways has a net margin of 0.00% compared to Immunocore's net margin of -5.70%. Immunocore's return on equity of -5.40% beat COMPASS Pathways' return on equity.

Company Net Margins Return on Equity Return on Assets
COMPASS PathwaysN/A -87.89% -57.77%
Immunocore -5.70%-5.40%-1.93%

In the previous week, Immunocore had 1 more articles in the media than COMPASS Pathways. MarketBeat recorded 3 mentions for Immunocore and 2 mentions for COMPASS Pathways. Immunocore's average media sentiment score of 1.51 beat COMPASS Pathways' score of 0.19 indicating that Immunocore is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
COMPASS Pathways
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Immunocore
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

46.2% of COMPASS Pathways shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 3.9% of COMPASS Pathways shares are held by company insiders. Comparatively, 10.4% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Immunocore beats COMPASS Pathways on 10 of the 15 factors compared between the two stocks.

Get COMPASS Pathways News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMPS vs. The Competition

MetricCOMPASS PathwaysMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$453.32M$7.73B$5.77B$9.77B
Dividend YieldN/A2.69%4.40%4.10%
P/E Ratio-2.5776.5430.3625.96
Price / SalesN/A50.25470.22121.97
Price / CashN/A25.5525.7828.78
Price / Book2.097.789.506.05
Net Income-$155.12M$242.04M$3.26B$265.21M
7 Day Performance10.75%-0.42%2.45%2.94%
1 Month Performance8.96%-0.11%3.97%1.33%
1 Year Performance-34.38%8.93%30.64%19.24%

COMPASS Pathways Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMPS
COMPASS Pathways
2.2396 of 5 stars
$4.70
+2.0%
$16.29
+246.4%
-35.9%$453.32MN/A-2.57120Positive News
IMCR
Immunocore
1.8159 of 5 stars
$32.31
-1.7%
$58.00
+79.5%
-7.9%$1.63B$310.20M-80.78320Positive News
Analyst Forecast
AUPH
Aurinia Pharmaceuticals
2.829 of 5 stars
$12.22
-0.4%
$12.00
-1.8%
+81.5%$1.61B$235.13M28.42300Positive News
CDTX
Cidara Therapeutics
3.6229 of 5 stars
$63.24
-3.0%
$64.14
+1.4%
+411.3%$1.60B$1.27M-5.6890Positive News
WVE
WAVE Life Sciences
4.7983 of 5 stars
$9.74
-0.2%
$20.27
+108.1%
+76.8%$1.55B$108.30M-10.82240Positive News
JANX
Janux Therapeutics
2.9727 of 5 stars
$25.53
+1.7%
$91.89
+259.9%
-47.1%$1.53B$10.59M-14.1830News Coverage
SDGR
Schrodinger
3.1151 of 5 stars
$20.05
+3.5%
$27.83
+38.8%
+2.3%$1.48B$207.54M-8.08790
EWTX
Edgewise Therapeutics
2.324 of 5 stars
$14.00
-1.1%
$41.60
+197.1%
-23.2%$1.47BN/A-9.0360
HROW
Harrow
3.5968 of 5 stars
$38.32
-1.3%
$64.67
+68.8%
-8.4%$1.42B$199.61M-153.28180Analyst Revision
ARDX
Ardelyx
4.2224 of 5 stars
$5.81
-2.7%
$11.50
+97.9%
-3.8%$1.40B$333.61M-25.2690
ETNB
89BIO
2.0295 of 5 stars
$9.44
+2.3%
$26.29
+178.5%
+6.5%$1.40BN/A-2.6140News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:CMPS) was last updated on 8/25/2025 by MarketBeat.com Staff
From Our Partners